Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel approach to detect the detailed effects of vildagliptin on beta-cell
2012-002230-37Phase 4Active
- Sponsor
- Erasmus MC
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of vildagliptin in prediabetes, impaired fasting glucose (IFG) and cardiac morbidity, sponsored by Erasmus MC. Primary endpoint: Effect of vildagliptin on beta-cell function. Started Dec 2013; status: active.
02
Drugs
vildagliptin
03
Conditions
prediabetesimpaired fasting glucose (IFG)cardiac morbidity
Beyond the preview
Go deeper on 2012-002230-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002230-37.